Bei Jing Shang Bao·2026-02-05 09:38Core Viewpoint - The restructuring of China-U.S. Bristol-Myers Squibb (BMS) marks a significant shift in the landscape of joint ventures in the pharmaceutical industry, driven by declining performance and strategic realignment [1][10]. Group 1: Share Transfer Details - Shanghai Pharmaceuticals plans to publicly transfer its 30% stake in China-U.S. Bristol-Myers Squibb through a property trading platform, with a minimum listing price of RMB 1.023 billion [1][5]. - BMS previously sold its 60% stake in the joint venture to Hillhouse Capital, with the transaction expected to complete in early 2026 [5][6]. - The transfer of shares is part of a broader trend where early joint ventures in the pharmaceutical sector are undergoing ownership changes and brand integrations [1][10]. Group 2: Financial Performance - China-U.S. Bristol-Myers Squibb's revenue has declined over 60% from its peak of nearly RMB 5 billion in 2016 to an estimated RMB 1.795 billion in 2024 [1][8]. - The company reported a net profit of only RMB 248 million in 2024, with revenues of RMB 1.096 billion in the first three quarters of 2025 [8][9]. - The decline in performance is attributed to market pressures and an aging product line, with key original drugs losing patent protection and facing competition from low-cost generics [9][11]. Group 3: Strategic Implications - The decision by Shanghai Pharmaceuticals to divest its stake is seen as a rational choice to maximize asset value and protect shareholder interests, particularly for minority shareholders [9][10]. - The shift in focus from mature drug businesses to innovative drug development aligns with the strategic direction of Shanghai Pharmaceuticals [9][11]. - The exit of early joint venture giants from the market reflects a significant transformation in the Chinese pharmaceutical landscape, driven by policy changes and evolving market dynamics [10][11].